Zercepac®
ACTIVE PRINCIPLE:
trastuzumab
INDICATION:
Breast cancer
Stomach cancer
DATE:
27/07/2020
STATUS:
Authorized
Biosimilar medicine authorized by the European Commission
ACTIVE PRINCIPLE:
trastuzumab
INDICATION:
Breast cancer
Stomach cancer
DATE:
27/07/2020
STATUS:
Authorized
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.